Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: a prognostic study
Authors' conclusion
Targeted DNA-based BM evaluated on routinely available FFPE samples improves prognostication of ACC beyond routinely available clinical and histopathological parameters. This approach may help to better individualise patient's management.
Study context
- Population
- Formalin-fixed, paraffin-embedded (FFPE) adrenocortical carcinoma (ACC) samples; retrospective training cohort and prospective validation cohortretrospective training cohort 107 · prospective validation cohort 87
- Participants
- 194 FFPE ACC samples
- Comparison
- Combined (COMBI) score vs S-GRAS score
- Outcome
- OS, PFS and DFS; prognostic performance compared by Harrell's C index
Methodological detailsretrospective training cohort, prospective validation cohort
- Retrospective training cohort
- Prospective validation cohort
Performance
As reported in the abstract
Discriminative prognostic performance (C index) for OS, PFS and DFS
- COMBI score was the best discriminative prognostic model in both cohorts for all endpoints, followed by S-GRAS score
Further findings
Independent prognostic role of DNA-based biomarkers (BMs) (Wnt/β-catenin and Rb/p53 pathway alterations; hypermethylated PAX5) for PFS and disease-free survival (DFS), training cohort, multivariate analysis
- HR
- 1.47-2.33
- P for PFS and DFS
- P < 0.05
Original publication
Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: a prognostic study. Eur J Endocrinol. Published 17 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →